Sertraline classification
Pro Research Analysisby 
Searched over 200M research papers for "sertraline classification"
Sertraline Classification: An Overview
Selective Serotonin Reuptake Inhibitor (SSRI)
Sertraline is classified as a selective serotonin reuptake inhibitor (SSRI), a class of drugs primarily used to treat depression and anxiety disorders. SSRIs function by inhibiting the reuptake of serotonin (5-hydroxytryptamine; 5-HT) in the brain, thereby increasing the availability of serotonin in the synaptic cleft and enhancing serotonergic neurotransmission Comer2000Murdoch1992Koe1983+1 MORE. This mechanism is believed to underlie the antidepressant and anxiolytic effects of sertraline.
Pharmacological Properties
Serotonin Transporter Inhibition
Sertraline is a potent and highly selective inhibitor of the serotonin transporter, with minimal effects on the noradrenaline (norepinephrine) and dopamine transporters Comer2000Koe1983. This selectivity contributes to its efficacy in treating various psychiatric conditions without significant interference with other neurotransmitter systems.
Receptor Affinity
Sertraline exhibits negligible affinity for a range of receptors, including serotonergic 5-HT1A, 5-HT1B, 5-HT2A, histaminergic H1, dopaminergic D1 and D2, muscarinic receptors, and α2- and β-adrenoceptors . This lack of affinity for these receptors helps minimize side effects commonly associated with other classes of antidepressants, such as anticholinergic and cardiovascular effects Koe1983Heym1988.
Clinical Applications
Depression and Anxiety Disorders
Sertraline is widely used for the treatment of major depressive disorder, panic disorder, and obsessive-compulsive disorder (OCD) Comer2000Murdoch1992Heym1988. It has demonstrated comparable efficacy to other antidepressants like amitriptyline and dothiepin, and superior efficacy to placebo in clinical trials . Additionally, sertraline is the only antidepressant licensed in the UK for the prevention of recurrence of depression .
Post-Traumatic Stress Disorder (PTSD)
Sertraline is also approved for the treatment of post-traumatic stress disorder (PTSD), particularly in female patients and those with non-combat-induced PTSD . Clinical trials have shown significant reductions in PTSD symptoms with sertraline treatment compared to placebo .
Night Eating Syndrome
In a randomized, placebo-controlled trial, sertraline was effective in treating night eating syndrome, significantly improving night eating symptoms, quality of life, and reducing nocturnal awakenings and ingestions .
Tolerability and Side Effects
Common Side Effects
Sertraline is generally well tolerated, with common side effects including gastrointestinal disturbances (nausea, diarrhea), insomnia, and male sexual dysfunction (primarily ejaculatory disturbance) Comer2000Murdoch1992Heym1988. These side effects are usually mild and transient, decreasing in frequency with continued treatment .
Safety Profile
Sertraline has a favorable safety profile, with minimal anticholinergic activity and no significant cardiovascular effects, making it suitable for elderly patients or those with underlying cardiovascular disorders Murdoch1992Koe1983. It also has a wide therapeutic index, further enhancing its safety in clinical use .
Conclusion
Sertraline, as a selective serotonin reuptake inhibitor, is a highly effective and well-tolerated medication for the treatment of various psychiatric disorders, including depression, anxiety disorders, PTSD, and night eating syndrome. Its selective inhibition of the serotonin transporter and minimal receptor affinity contribute to its efficacy and favorable side effect profile, making it a valuable option in psychopharmacology.
Sources and full results
Most relevant research papers on this topic